These same biomarkers are also of interest in traumatic brain injury (TBI), which is recognized as a modifiable risk factor for dementia,2 and where glial fibrillary acidic protein (GFAP), in combination with ubiquitin carboxyl‐terminal hydrolase L1 (UCHL1), is cleared for clinical use in the acute injury setting. The gene discussed is GFAP; the disease is dementia.